Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 52:1769-1781, doi:10.1016/j.jacc.2008.08.039
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mills, E. J.
Right arrow Articles by Perri, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mills, E. J.
Right arrow Articles by Perri, D.
Related Collections
Right arrowRelated Article

CLINICAL RESEARCH: PREVENTIVE CARDIOLOGY

Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments

A Network Meta-Analysis Involving More Than 65,000 Patients

Edward J. Mills, MSc, PhD, LLM*,*, Beth Rachlis, MSc§, Ping Wu, MBBS, MSc||, Philip J. Devereaux, MD, PhD*,{dagger}, Paul Arora, MSc and Dan Perri, BScPharm, MD, FRCP(C){dagger},{ddagger}

* Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
{dagger} Department of Medicine, McMaster University, Hamilton, Ontario, Canada
{ddagger} Centre for Evaluation of Medicines, McMaster University, Hamilton, Ontario, Canada
§ Department of Healthcare and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
|| Department of Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
Centre for Global Health, University of Toronto, Toronto, Ontario, Canada

Manuscript received July 1, 2008; revised manuscript received August 20, 2008, accepted August 25, 2008.

* Reprint requests and correspondence: Dr. Edward J. Mills, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada (Email: millsej{at}mcmaster.ca).

Objectives: This study aimed to evaluate the effectiveness of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins) in primary prevention of cardiovascular events.

Background: The role of statins is well established for secondary prevention of cardiovascular disease (CVD) clinical events and mortality. Little is known of their role in primary cardiovascular event prevention.

Methods: We conducted comprehensive searches of 10 electronic databases from inception to May 2008. We contacted study investigators and maintained a comprehensive bibliography of statin studies. We included randomized trials of at least 12-month duration in predominantly primary prevention populations. Two reviewers independently extracted data in duplicate. We performed random-effects meta-analysis and meta-regression, calculated optimal information size, and conducted a mixed-treatment comparison analysis.

Results: We included 20 randomized clinical trials. We pooled 19 trials (n = 63,899) for all-cause mortality and found a relative risk (RR) of 0.93 (95% confidence interval [CI]: 0.87 to 0.99, p = 0.03 [I2 = 5%, 95% CI: 0% to 51%]). Eighteen trials (n = 59,469) assessed cardiovascular deaths (RR: 0.89, 95% CI: 0.81 to 0.98, p = 0.01 [I2 = 0%, 95% CI: 0% to 41%]). Seventeen trials (n = 53,371) found an RR of 0.85 (95% CI: 0.77 to 0.95, p = 0.004 [I2 = 61%, 95% CI: 38% to 77%]) for major cardiovascular events, and 17 trials (n = 52,976) assessed myocardial infarctions (RR: 0.77, 95% CI: 0.63 to 0.95, p = 0.01 [I2 = 59%, 95% CI: 24% to 74%]). Incidence of cancer was not elevated in 10 trials (n = 45,469) (RR: 1.02, 95% CI: 0.94 to 1.11, p = 0.59 [I2 = 0%, 95% CI: 0% to 46%]), nor was rhabdomyolysis (RR: 0.97, 95% CI: 0.25 to 3.83, p = 0.96 [I2 = 0%, 95% CI: 0% to 40%]). Our analysis included a sufficient sample to reliably answer our primary outcome of CVD mortality.

Conclusions: Statins have a clear role in primary prevention of CVD mortality and major events.

Key Words: statins • meta-analysis • primary prevention

Abbreviations and Acronyms
  CHD = coronary heart disease
  CI = confidence interval
  CrI = credibility interval
  CVD = cardiovascular disease
  HDL = high-density lipoprotein
  IQR = interquartile range
  LDL = low-density lipoprotein
  MI = myocardial infarction
  OIS = optimal information size
  RR = relative risk


Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A36. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Am J EpidemiolHome page
G. Danaei, M. Tavakkoli, and M. A. Hernan
Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins
Am. J. Epidemiol., February 15, 2012; 175(4): 250 - 262.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
M. Alberton, P. Wu, E. Druyts, M. Briel, and E. J. Mills
Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis
QJM, February 1, 2012; 105(2): 145 - 157.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Developed with the special contribution of: Europe, Authors/Task Force Members, Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, et al.
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Eur. Heart J., July 2, 2011; 32(14): 1769 - 1818.
[Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
D. K. Bowles and M. H. Laughlin
Mechanism of beneficial effects of physical activity on atherosclerosis and coronary heart disease
J Appl Physiol, July 1, 2011; 111(1): 308 - 310.
[Full Text] [PDF]


Home page
Eur Heart JHome page
E. J. Mills, C. O'Regan, O. Eyawo, P. Wu, F. Mills, O. Berwanger, and M. Briel
Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients
Eur. Heart J., June 1, 2011; 32(11): 1409 - 1415.
[Abstract] [Full Text] [PDF]


Home page
European Journal of Cardiovascular Prevention & RehabilitationHome page
T. Tomasik, J. Jozwiak, A. Windak, K. Rygiel, M. Mastej, W. H. Smithson, N. Mathers, M. Tomaszewski, B. M. Kaess, A. Tykarski, et al.
Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study
European Journal of Cardiovascular Prevention & Rehabilitation, April 1, 2011; 18(2): 287 - 296.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J. Greving, F. Visseren, G. de Wit, and A. Algra
Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
BMJ, March 30, 2011; 342(mar30_3): d1672 - d1672.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. J. Jacobs, C. C. Newton, M. J. Thun, and S. M. Gapstur
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Cancer Res., March 1, 2011; 71(5): 1763 - 1771.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J. W. Deckers and R. S. Blumenthal
Statins for primary prevention of cardiovascular disease
BMJ, February 16, 2011; 342(feb16_1): d1048 - d1048.
[Full Text]


Home page
Diabetes CareHome page
A. Chait and V. N. Montes
Apolipoproteins and Diabetic Retinopathy
Diabetes Care, February 1, 2011; 34(2): 529 - 531.
[Full Text] [PDF]


Home page
QJMHome page
E. J. Mills, P. WU, G. Chong, I. Ghement, S. Singh, E. A. Akl, O. Eyawo, G. Guyatt, O. Berwanger, and M. Briel
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials
QJM, February 1, 2011; 104(2): 109 - 124.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. J. Brugts and J. W. Deckers
Statins and All-Cause Mortality in High-Risk Primary Prevention of Patients With Cardiovascular Risk Factors
Arch Intern Med, December 13, 2010; 170(22): 2041 - 2041.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Vaduganathan, N. J. Stone, R. Lee, E. C. McGee Jr., S. C. Malaisrie, R. A. Silverberg, and P. M. McCarthy
Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery
J. Thorac. Cardiovasc. Surg., November 1, 2010; 140(5): 1018 - 1027.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. E. Winchester, X. Wen, L. Xie, and A. A. Bavry
Evidence of Pre-Procedural Statin Therapy: A Meta-Analysis of Randomized Trials
J. Am. Coll. Cardiol., September 28, 2010; 56(14): 1099 - 1109.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
L. Bjorck, L. Wallentin, U. Stenestrand, G. Lappas, and A. Rosengren
Medication in Relation to ST-Segment Elevation Myocardial Infarction in Patients With a First Myocardial Infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)
Arch Intern Med, August 9, 2010; 170(15): 1375 - 1381.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
K. K. Ray, S. R. K. Seshasai, S. Erqou, P. Sever, J. W. Jukema, I. Ford, and N. Sattar
Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants
Arch Intern Med, June 28, 2010; 170(12): 1024 - 1031.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. M. Psaty
Drug Therapies for the Primary Prevention of Cardiovascular Events: Trials and Errors: 2009 Ancel Keys Memorial Lecture
Circulation, February 23, 2010; 121(7): 940 - 945.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Pignatelli, R. Carnevale, R. Cangemi, L. Loffredo, V. Sanguigni, C. Stefanutti, S. Basili, and F. Violi
Atorvastatin Inhibits gp91phox Circulating Levels in Patients With Hypercholesterolemia
Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 360 - 367.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Khan, M. P. Hamilton, D. I. Mundy, S. C. Chua, and P. E. Scherer
Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo
Endocrinology, December 1, 2009; 150(12): 5262 - 5272.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. S. Rossi and H. L. McLeod
The Pharmacogenetics of Statin Therapy: When the Body Aches, the Mind Will Follow
J. Am. Coll. Cardiol., October 20, 2009; 54(17): 1617 - 1618.
[Full Text] [PDF]


Home page
European Journal of Cardiovascular Prevention & RehabilitationHome page
F. D. R. Hobbs, G. Gensini, G. B. J. Mancini, A. J. Manolis, B. Bauer, J. Genest, R. D. Feldman, P. Harvey, T. G. Jenssen, P. M. d. Silva, et al.
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme
European Journal of Cardiovascular Prevention & Rehabilitation, August 1, 2009; 16(4): 472 - 480.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J J Brugts, T Yetgin, S E Hoeks, A M Gotto, J Shepherd, R G J Westendorp, A J M de Craen, R H Knopp, H Nakamura, P Ridker, et al.
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
BMJ, June 30, 2009; 338(jun30_1): b2376 - b2376.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. F. Muldoon
Trial Evidence for Statin-Based Primary Prevention Remains Dubious
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2312 - 2312.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. J. Mills and P. J. Devereaux
Reply
J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2312 - 2313.
[Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
S. H Song and T. A Gray
Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008
The British Journal of Diabetes & Vascular Disease, March 1, 2009; 9(2): 69 - 74.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement